secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001558370-24-002113
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios reports FY2023 net loss $5.3M, down 57% YoY; FDA aligns on Long-COVID endpoint for IMC-2
--------------------------------------------------------------------------------

- Net loss for FY2023 $5.3M ($0.28/share), down from $12.2M ($1.11/share) in FY2022.
- R&D expenses $1.7M in FY2023 vs $8.1M in FY2022, driven by lower clinical trial costs.
- Cash at Dec 31, 2023: $3.3M; expected to fund operations into Q4 2024.
- FDA agreed to use fatigue as primary endpoint for IMC-2 Phase 2 in Long-COVID; initiation targeted H2 2024, pending funding.
- Placebo-controlled data on valacyclovir/celecoxib for Long-COVID from Bateman Horne Center expected summer 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024002113/0001558370-24-002113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024002113/tmb-20240229x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-002113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer